Bechtel Medical's Innovative Wound VOX™ Secures FDA Clearance for Enhanced Wound Care Solutions
In an important stride for wound care technology, Bechtel Medical has recently received FDA clearance for its innovative product, Wound VOX™, the first combined system utilizing both Negative Pressure Wound Therapy (NPWT) and Topical Oxygen Therapy (TOT). This marked a significant advancement in the Advanced Wound Care sector, where Bechtel Medical has established a strong reputation for its commitment to improving patient outcomes. Founded in Phoenixville, Pennsylvania, the company has made it their mission to enhance the quality of life for patients dealing with complex wounds.
Negative Pressure Wound Therapy has been recognized for decades as a 'Gold Standard' treatment option for a variety of challenging wounds. The therapy involves the application of sub-atmospheric pressure to a wound site, which helps to facilitate healing by improving blood flow, reducing edema, and decreasing the bacterial load. Over the past fifteen years, a complementary approach known as Topical Oxygen Therapy has garnered attention for its potential benefits in promoting wound healing. However, while TOT has shown promise, it still faces reimbursement challenges and is not as widely adopted as NPWT.
Bechtel Medical's Wound VOX™ addresses this issue by integrating both therapies into a single platform. The device operates in three distinct modes: continuous NPWT, intermittent NPWT, and intermittent NPWT combined with adjunctive TOT. This integration reduces the operational complexity traditionally associated with using separate systems for each therapy. By streamlining the process, Wound VOX™ aims to improve the clinician's ability to deliver effective wound care without the added difficulty of managing multiple devices.
Recent independent research has emphasized the potential benefits of combining NPWT and TOT. A systematic review and meta-analysis published in 2025 in the journal Advances in Wound Care evaluated various randomized controlled trials. The findings suggested that patients receiving combination treatment experienced significantly higher rates of complete wound healing and reduced bacterial positivity when compared to NPWT alone. While these studies did not specifically test Wound VOX™, they signal a positive trend towards the effectiveness of combining treatment modalities.
John Gvodas, the Founder and CEO of Bechtel Medical, stated, "Treating hard-to-heal wounds with both negative pressure and concentrated oxygen has historically required clinicians to manage separate systems, adding complexity to an already challenging clinical problem. We designed Wound VOX™ to integrate these two therapeutic technologies into a single platform, with the goal of simplifying the delivery of advanced wound care while addressing some of the operational and economic barriers that have historically limited access to these therapies."
Looking ahead, Bechtel Medical plans to execute a limited commercial release of the Wound VOX™ in December 2026. The company is keen on enabling clinicians and potential durable medical equipment (DME) distribution partners to learn more about the product and how it can enhance patient care.
Bechtel Medical's ongoing commitment to responsible innovation and patient safety is evident in their focus on addressing unmet clinical needs. The organization operates under high standards of quality and compliance, ensuring that their products deliver on their promises. For more information about Wound VOX™ and its features, stakeholders can visit their website at woundvox.com.
As the landscape of medical technology continues to evolve, products like Wound VOX™ represent a crucial advancement in wound management, paving the way for better patient outcomes and more efficient clinical practices. With FDA clearance now secured, Bechtel Medical is poised to make a significant impact in the realm of advanced wound care.
Negative Pressure Wound Therapy has been recognized for decades as a 'Gold Standard' treatment option for a variety of challenging wounds. The therapy involves the application of sub-atmospheric pressure to a wound site, which helps to facilitate healing by improving blood flow, reducing edema, and decreasing the bacterial load. Over the past fifteen years, a complementary approach known as Topical Oxygen Therapy has garnered attention for its potential benefits in promoting wound healing. However, while TOT has shown promise, it still faces reimbursement challenges and is not as widely adopted as NPWT.
Bechtel Medical's Wound VOX™ addresses this issue by integrating both therapies into a single platform. The device operates in three distinct modes: continuous NPWT, intermittent NPWT, and intermittent NPWT combined with adjunctive TOT. This integration reduces the operational complexity traditionally associated with using separate systems for each therapy. By streamlining the process, Wound VOX™ aims to improve the clinician's ability to deliver effective wound care without the added difficulty of managing multiple devices.
Recent independent research has emphasized the potential benefits of combining NPWT and TOT. A systematic review and meta-analysis published in 2025 in the journal Advances in Wound Care evaluated various randomized controlled trials. The findings suggested that patients receiving combination treatment experienced significantly higher rates of complete wound healing and reduced bacterial positivity when compared to NPWT alone. While these studies did not specifically test Wound VOX™, they signal a positive trend towards the effectiveness of combining treatment modalities.
John Gvodas, the Founder and CEO of Bechtel Medical, stated, "Treating hard-to-heal wounds with both negative pressure and concentrated oxygen has historically required clinicians to manage separate systems, adding complexity to an already challenging clinical problem. We designed Wound VOX™ to integrate these two therapeutic technologies into a single platform, with the goal of simplifying the delivery of advanced wound care while addressing some of the operational and economic barriers that have historically limited access to these therapies."
Looking ahead, Bechtel Medical plans to execute a limited commercial release of the Wound VOX™ in December 2026. The company is keen on enabling clinicians and potential durable medical equipment (DME) distribution partners to learn more about the product and how it can enhance patient care.
Bechtel Medical's ongoing commitment to responsible innovation and patient safety is evident in their focus on addressing unmet clinical needs. The organization operates under high standards of quality and compliance, ensuring that their products deliver on their promises. For more information about Wound VOX™ and its features, stakeholders can visit their website at woundvox.com.
As the landscape of medical technology continues to evolve, products like Wound VOX™ represent a crucial advancement in wound management, paving the way for better patient outcomes and more efficient clinical practices. With FDA clearance now secured, Bechtel Medical is poised to make a significant impact in the realm of advanced wound care.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.